A recap of all the innovation happening at the Texas Medical Center, innovators to know, and Houston startup news trended this week. Courtesy of TMC

Editor's note: This week was full of innovation events — and there's many more coming up this month. Event coverage, innovators to know, and more startup news trended on InnovationMap this week.

3 Houston innovators to know this week

Meet this week's Houston innovators to know. Courtesy photos

This week, some key Houston innovators to know include the CEO of a tech company that's demystifying Google's SEO, a local entrepreneur who just raised millions in funding, and the newest addition to the Houston innovation ecosystem. Continue reading.

From robots to immunotherapy, TMC talks innovation at its annual address

The Texas Medical Center's CEO, Bill McKeon, ran down a list of exciting updates and innovations from the organization's member institutions at the annual State of the TMC. Photo via tmc.edu

In the Greater Houston Partnership's annual State of the Texas Medical Center address, TMC CEO Bill McKeon shared a status update of sorts for all the goings on at the largest medical center in the world.

McKeon ran down the list of member institutions to briefly touch base on each organization's innovations and growth. In the address, which took place at the Marriott Marquis on October 31, McKeon discussed exciting construction projects, new accelerator programs, and more. Continue reading.

Exclusive: The Cannon Houston restructures, brings on new executive to lead operations

Just after celebrating its new 200,000-square-foot flagship location, The Cannon Houston has named a new CEO to further grow the coworking space and startup hub. Photo courtesy of The Cannon

After celebrating the opening its flagship coworking space the same week it announced another location in downtown, startup hub and coworking company, The Cannon Houston, has another big announcement: a new CEO.

A former global consultant for KPMG, Jon Lambert has been named The Cannon's CEO. He will also support day-to-day operations at The Cannon's three locations. Meanwhile, Lawson Gow, founder of the company and former CEO, will move to president of The Cannon. Gow, who is the son of InnovationMap's parent company's CEO, will focus on partnerships and business development, as well as continuing to be the face of the company. Continue reading.

Houston biomedical startup granted $1.5M, Chevron taps into Plug and Play, and more innovation news

Money moves, big deals, and more lead this roundup of innovation news. Pexels

Hitting headlines this month are innovation news stories from battling the opioid crisis and funding to TMCx companies and Houston as a whole earning recognition. In this innovation news roundup, two Houston startups pocket some cash, Chevron links up with Plug and Play, and more. Continue reading.

10+ can't-miss Houston business and innovation events for November

From enlightening talks and conventions to networking opportunities, here's where you need to be in November. Getty Images

Looking for some help navigating an innovation-filled month in Houston? Look no further.

November is jam packed with Houston business and innovation events — from huge conventions like SpaceCom and Global Corporate Venture taking over downtown on the same days to the Digital Fight Club battling it out in Houston for the first time and The Houston Innovation Summit planning a week of programming. Continue reading.

A new robotics facility is headed for the TMC Innovation Institute. Courtesy of TMC

TMC plans to open one-of-its-kind robotics facility later this year

The robots are coming

The Texas Medical Center has announced its plans to open a new robotics-equipped laboratory in October of this year. The automation capabilities will allow for more efficient lab tests and services.

The new facility is being made possible by a partnership between the medical center, TMC Innovation Institute, and ABB, a leading robotics company. This would be Zürich-based ABB's first dedicated health care center, but the company has over 400,000 robotics products across industries in over 53 countries.

"The next-generation laboratory processes developed in Houston will speed manual medical laboratory processes, reducing and eliminating bottlenecks in laboratory work and enhancing safety and consistency," says Sami Atiya, president of ABB's Robotics and Discrete Automation business, in a news release. "This is especially applicable for new high-tech treatments, such as the cancer therapies pioneered at the Texas Medical Center, which today require manual and time-consuming test processes."

A team of 20 will work out of the 5,300-square-foot facility, which will be located in TMC Innovation Institute. The space will have an automation laboratory with robot training facilities, and meeting spaces for the human innovation partners.

Currently, ABB's robots specialize in food and beverage laboratories worldwide, but able to adapt to medical facilities for specific tasks, including "dosing, mixing, and pipetting tasks, as well as sterile instrument kitting and centrifuge loading and unloading," according to the release.

"We are proud to co-develop collaborative robotics systems for the hospital of the future with one of the world's most advanced partners and to test them in real-world laboratories to ensure they add value to healthcare professionals, driving innovation, and transforming how medical laboratories operate worldwide," says Atiya in the release.

According to the release, TMC's connection to innovation, startups, and researchers were key factors in bringing the facility to Houston. ABB Robotics has a long-term plan to invest and innovate in robotics, says Atiya in the release.

"The Texas Medical Center continues to push the boundaries of innovation with cutting-edge industry partners by establishing TMC as the epicenter for ABB Robotics' entry into the healthcare space," says Bill McKeon, president and CEO of Texas Medical Center, in the release. "We continually strive for opportunities to accelerate research and enhance clinical care through key strategic partnerships. ABB's move into the heart of the Texas Medical Center campus with this first-of-its-kind R&D facility for creating robotics solutions in healthcare will set a new course for advancements in medicine."

Automation nation

Courtesy of TMC

A team of 20 will work out of the 5,300-square-foot facility, which will be located in TMC Innovation Institute.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.